During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Norbert Vey, Institut Paoli-Calmettes, Marseilles, FR. We asked: How has the treatment landscape of acute myeloid leukemia evolved in the last five years?
Norbert Vey talks about the new drugs that have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia. He discusses the new regimens that are being explored to treat patients, that historically had a dismal prognosis, in hope for better response and overall survival. He also explains the evolving diagnostic techniques (e.g. minimal residual disease status) that are being used to guide AML treatment pathway.